Article | August 19, 2021

Moving Forward In Immuno-Dermatology: Clinical Trial Considerations

By David A. Amato, DO, FAAD, Senior Medical Director, IQVIA Biotech

iStock-1152216276-skin-dermatology

As the use of immunotherapies and biologics expand across dermatology indications, make sure you know the specific considerations for your clinical trial

As the science underpinning dermatological conditions has become more thoroughly understood, new therapeutic pathways have been identified and treatment options have rapidly evolved into biologic therapeutics and beyond. The first biologic approved for a dermatological indication was Amevive® for psoriasis in 2003. Today, there are more than 10 drugs on the market to treat psoriasis alone.1 Some biologics, such as dupilumab, have also been trialed for conditions outside of dermatology, such as asthma,2 eosinophilic esophagitis,3 and nasal polyposis.4

The global commercial dermatology market will continue to thrive, and is estimated to reach $33.7 billion by 2022, rising at a 7.73 percent compound annual growth rate from 2015 to 2022.7 With this momentum and the continued need for safe and effective dermatology treatments, it’s important to understand the strategic needs of clinical trials using novel immuno-dermatology agents.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader